Retrospective evaluation of the "neutrophil-lymphocyte ratio" (NLR) in patients affected by locally advanced unresectable stage III NSCLC treated with Durvalumab within the Italian expanded access program (EAP): results of the neutrality trial
{{output}}
Background: Very little is known regarding the clinical value of inflammatory blood markers, such as NLR, Systemic Immune Inflammation (SII), derived NLR (dNLR) and Lung Immune Prognostic Index (LIPI) in stage III NSCLC patients ... ...
